Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioadaptives (BDPT) Accounts Payables (2019 - 2025)

Bioadaptives' Accounts Payables history spans 7 years, with the latest figure at $230768.0 for Q3 2025.

  • For Q3 2025, Accounts Payables fell 51.26% year-over-year to $230768.0; the TTM value through Sep 2025 reached $230768.0, down 51.26%, while the annual FY2024 figure was $179458.0, 59.54% down from the prior year.
  • Accounts Payables for Q3 2025 was $230768.0 at Bioadaptives, up from $204081.0 in the prior quarter.
  • Across five years, Accounts Payables topped out at $473501.0 in Q3 2024 and bottomed at $57258.0 in Q1 2021.
  • The 5-year median for Accounts Payables is $391399.0 (2022), against an average of $316179.9.
  • The largest annual shift saw Accounts Payables skyrocketed 467.47% in 2022 before it tumbled 59.54% in 2024.
  • A 5-year view of Accounts Payables shows it stood at $247750.0 in 2021, then soared by 65.46% to $409920.0 in 2022, then grew by 8.21% to $443579.0 in 2023, then crashed by 59.54% to $179458.0 in 2024, then rose by 28.59% to $230768.0 in 2025.
  • Per Business Quant, the three most recent readings for BDPT's Accounts Payables are $230768.0 (Q3 2025), $204081.0 (Q2 2025), and $196816.0 (Q1 2025).